ProTECT III - Progesterone for the Treatment of Traumatic Brain Injury
Research to study the effectiveness of the hormone progesterone in reducing brain damage in patients with moderate to severe traumatic brain injury in Milwaukee County, called the ProTECT III Trial, will begin in March 2010.
Traumatic Brain Injury contributes significantly to the death and disability of millions of United States citizens. The medication will be administered by Froedtert Hospital staff. The standard of care will be equal to current standards.
This study meets the FDA guidelines for exception to informed consent under emergency circumstances because prior informed consent cannot be obtained from a patient experiencing traumatic brain injury.
For details, on the risks and benefits, exception from informed consent under emergency circumstances, opt-out bracelets and other aspects of the study please call Dr. Tom Aufderheide at (414) 805-6493, e-mail at email@example.com.